Skip to main content

Table 2 Drug likeness of the potential inhibitors from swissadme server

From: Prospect into therapeutic potentials of Moringa oleifera phytocompounds against cancer upsurge: de novo synthesis of test compounds, molecular docking, and ADMET studies

Compound ID Molecular weight Hydrogen bonds RotatableBonds LogP (iLogPo/w) TPSA RO5 violation
Donor Acceptor
ML2 128.26 0 0 3 2.79 0a 1
ML4 161.24 1 0 3 2.66 12.36 0
ML5 206.32 1 1 2 2.86 20.23 0
ML6 240.42 1 1 14a 4.23 20.23 1
ML7 296.53 1 1 13a 4.66 20.23 1
ML8 270.45 2 0 15a 4.41 26.3 1
ML9 652.94a 8 2 34a 7.58 119.36 2
ML10 296.53 1 1 13a 4.66 20.23 1
ML11 282.46 2 1 15a 4.27 37.3 1
ML12 324.54 2 0 12a 4.85 26.3 1
ML13 883.42a 6 0 51a 11.69 78.9 2
ML14 252.44 1 0 13a 4.07 17.07 1
ML15 390.56 4 0 18a 4.14 52.6 1
MS1 270.45 2 0 15a 4.41 26.3 1
MS2 652.94a 8 2 34a 7.58 119.36 2
MS3 296.49 2 0 16a 4.75 26.3 1
MS4 282.46 2 1 15a 4.27 37.3 1
MS5 281.48 1 1 15a 4.22 43.09 1
  1. aRO5 (Lipinski rule of five) violations, TPSA topological polar surface area, Log P octanol–water partition coefficient